FDA Advisory Panel Begins Review to Loosen Restrictions on Unapproved Peptides Amid Safety Concerns
Key Insights
An FDA advisory committee convened a two-day meeting to consider lifting a ban and widening access to seven popular but unapproved peptides, including BPC-157.
The panel has already voted to broaden access to at least one peptide, BPC-157, despite the absence of any controlled human studies supporting its use.
Dr. Dhruv Khullar of Weill Cornell Medicine warned that making these peptides accessible without clinical studies will make it harder to determine their actual effects and risks in the body.
An FDA advisory committee began a two-day meeting today to consider lifting a ban and widening access to seven popular peptides, marking a pivotal moment in the regulatory oversight of compounds that have surged in popularity through social media and wellness influencer promotion.
The meeting comes three years after the FDA blocked compounding pharmacies from producing these specific peptides, citing inadequate evidence of their safety and efficacy. While some peptides are FDA-approved and widely used — including insulin and GLP-1 receptor agonists — the seven under review remain unapproved and have not undergone rigorous clinical study.
Committee Vote and Conflict of Interest Concerns
The advisory panel has already voted to broaden access to at least one of the peptides under consideration: BPC-157, or Body Protection Compound-157. The committee heard testimony from a range of speakers, including scientists who argued against making the compound more accessible, though the majority of voices were reportedly doctors, chemists, and peptide business owners who pushed for approval.
Dr. Dhruv Khullar, a physician with Weill Cornell Medicine and author of a New Yorker article on peptide use, raised concerns about the composition of the committee itself.
"We know that some of the people who are on the committee that's making these recommendations do have conflicts of interest," Khullar said. "They are either people who have been involved in the compounding pharmacy industry or otherwise involved with peptides. And so that creates serious concerns about the recommendations that are coming forward."
Scientific Evidence Gap
BPC-157, one of the most commonly used and widely recognized of these unapproved peptides, does not have a single controlled human study to support its use, according to Khullar. While there are theoretical reasons and animal studies suggesting potential benefits, significant safety questions remain unresolved.
"For instance, one of the things that BPC-157 does is promote angiogenesis, and that is helpful for tissue repair and recovery," Khullar explained. "But it also allows cancerous cells to grow. Cancers are hungry for blood vessels, and angiogenesis is the process by which blood vessels are formed. And so, without doing the requisite studies, we're not going to know what the potential benefits are and what the risks are of this compound."
The Rise of Peptide Use and Influencer Promotion
Peptides are essentially microproteins — chains of fewer than approximately 50 amino acids — that the body naturally produces to regulate various systems and send signals between cells. The unapproved peptides under review have gained traction largely through social media, where influencers have made sweeping claims about their benefits.
Influencers have asserted that these peptides can enhance strength, improve energy and recovery, produce better tans, increase libido, and improve skin elasticity and collagen production. One influencer claimed, "I actually dropped almost 20 pounds in just a few weeks," while another stated, "The peptide I can give you, and within a day, you will be tanner than you have ever been tanned."
Khullar acknowledged the possibility that some peptides could have clinical value but emphasized the need for proper evaluation. "We should be open to the idea that some of these peptides could have important clinical uses in people. But we need to do the work to figure out at what doses should they be taken, who should be taking them, do they actually produce the types of effects that people are claiming that they produce? We don't know any of those things."
Political Support and Regulatory Debate
The push to expand peptide access has gained high-profile backing. Health and Human Services Secretary Robert F. Kennedy Jr. discussed his personal peptide use on a podcast in February, stating, "I'm a big fan of peptides. I have used them myself and used them with really good effect on a couple of injuries." Kennedy expressed hope that the science would support moving peptides "to a place where people have access from ethical suppliers."
The 2023 ban under the previous administration, which restricted compounding pharmacies from producing these peptides, was intended to address the lack of clinical data on safety and efficacy. Kennedy has argued that the ban created "gray and black markets."
Khullar pushed back on that reasoning: "The argument about we're not going to allow things happening, and that's pushing things into a gray market, that could be used for all sorts of things that we don't otherwise allow. I mean, you think about something like fentanyl or heroin. No one argues that we should make those legal and accessible just because banning them somehow moves them into the gray market."
Implications for Future Research
A central concern raised during the proceedings is that broadening access without requiring clinical studies could paradoxically hinder scientific understanding of these compounds.
"By making these things easily accessible without requiring any clinical study, it's going to make it harder still to figure out what they're actually doing inside the body," Khullar said.
The FDA advisory committee's deliberations continue as the agency weighs the balance between public demand for expanded access and the regulatory standards that govern drug safety and efficacy in the United States.